| [1] | Parise LV, Telen MJ. Erythrocyte adhesion in sickle cell. Disease. Curr Hematol 2003; (2); 102-8. |
| [2] | Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin Hematol 2006; 13(1):40-4. |
| [3] | Johinson L, Carmona-Bayonas A, Tick L. management of pain due to sickle cell disease. J pain palliat care pharmacother. 2008; 22(1):51-4. |
| [4] | Chaing EY, Frenette PS. Sickle cell vaso-occlusion. Hematol oncol clin north Am. Oct. 2005; 19(5); 771-84. |
| [5] | Chaing EY, Frenette PS. Sickle cell vaso-occlusion. Hematol oncol clin north Am. Oct. 2005; 19(5); 771-84. |
| [6] | Zen Q, Batchvarova M, Twyman CA, Eyler CE, Qiu H, De Castro LM, et al. B-CAM/LU expression and the role of B-CAM/LU activation in binding of low and high density red cell to laminin in sickle cell disease. Am J Hematol, Feb 2004; 75(2):63-72. |
| [7] | Albers, G. W., Caplan, L. R., Easton, J. D., Fayad, P. B., Mohr, J. P., Saver, J. L., et al. (2002). Transientischemic attack–proposal for a new definition. New England Journal of Medicine, 347, 1713–1716 at 2011 .sep 159(3); 472-8. J Pea |
| [8] | Hines PC. Mcknight TP, Scto W.CNS event inSC |
| [9] | Winnow N, Meiham ER.SCD and Stroke in pediatric population. Neuroimaging Clini.NAM; 2003 may, 13(2); 185-96. |
| [10] | Ganesan V et al. (2006) Recurrence after childhood ischemic stroke.circulation.114; 2170-2177. |
| [11] | Makani J (2004) Stroke in sickle cell disease in Africa: case report. East Afr Med J 81: 657-659. |
| [12] | Adams, R., McKie, V., Nichols, F., Carl, E., Zhang, D. L., McKie, K., et al. (1992). The use of trans cranial ultrasonography to predict stroke in sickle cell disease. New England Journal of Medicine, 326, 605–610. |
| [13] | Hsu LL et al. (2003) Alpha thalassemia is associated with decreased risk of abnormal trans cranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 25: 622-628. |
| [14] | Adams RJ, Nichols FT, Stephens S, et al. Trans cranial Doppler: the influence of age and hematocrit in normal children. J Cardiovasc Ultrasonogr. 1988; 7(3): 201-205. |
| [15] | Robert J. Adams, MS, MD Big Strokes in Small Persons Arch Neurol. 2007; 64(11):1567-1574. |
| [16] | Scothorn, D. J., Price, C., Schwartz, D., Terrill, C., Buchanan, G. R., Shurney, W., et al. (2002). Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. Journal of Pediatrics, 140, 348–354. |
| [17] | Nelson textbook of pediatrics, 19 ed. chapter 456.1 Sickle Cell Disease Michael R. DeBaun, Melissa Frei-Jones. |
| [18] | Buchanan, G. R., DeBaun, M. R., Quinn, C. T., & Steinberg, M. H. (2004). Sickle cell disease. Hematology (American Society of Hematology Education Program), 35–47. |
| [19] | Bernaudin, F., Verlhac, S., Freard, F., Roudot-Thoraval, F., Benkerrou, M., Thuret, I., et al. (2000). Multicenter prospective study of children with sickle cell disease: Radiographic and psychometric correlation. Journal of Child Neurology, 15, 333–343. |
| [20] | Bakhshi S etal .Acute encephalopathy in sickle cel disease. Arch Dis Child (2003) 87; 541-542. |
| [21] | Robert J. Adams. Big Stroke in Small Persons. Arch Neurol, 2007; 64(11); 1567-1574. |
| [22] | Steinberg MH. Brugnara Pathophysiological-based approaches to treatment of sickle cell disease. Annu Rev Med.2003; 54; 99-112 |
| [23] | Robert J. Adams, MS, MD Big Strokes in Small Persons ArchNeurol.2007; 64(11):1567-1574 |
| [24] | Editors: Rudolph, Colin D.; Rudolph, Abraham M.; Hostetter, Margaret K.; Lister, George; Siegel, Norman J. Title: Rudolph's Pediatrics, 21st Edition, Chapter 19 - Blood and Bloodâ “forming Tissues, 1532-39. |
| [25] | Platt OS. Preventing stroke in sickle cell anemia. N Engl JMed. 2005; 353(26): 2743- 2745. |
| [26] | Setty BY etal .Hypoxemia in sickle cell disease; biomarker modulation and relevance to disease pathophysiology (2003). Lancet 362; 1450-1455 |
| [27] | Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions to prevent stroke in sickle cell disease. N Engl J Med. 2005; 353(26): 2769-2778. |
| [28] | Ware RE etal. Prevention of secondary stroke and resolution of transfusion iron overload in children with SCD using Hydroxyurea and phlebotomy. (2004). J Peadiatr 145; 346-352. |
| [29] | Scothorn, D. J., Price, C., Schwartz, D., Terrill, C., Buchanan, G. R., Shurney, W., et al. (2002). Risk of recurrent stroke in children with sickle cell receiving blood transfusion therapy for at least five years after initial stroke. Journal of Pediatrics, 140, 348–354. |
| [30] | Adette INATI. managment of iron toxicity in sickle cell disease; issue, options, and guidance.Iron Journal Club.vol 3; NO2; 2009; 75-79. |
| [31] | Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequale of intravascular hemolysis; anovel mechanisim of human disease. JAMA, 2005; 293(13); 1653-1662. |
| [32] | Gulbis B, Haberman D, Dufour D, etal. use of Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events; Blood .2005;105;2685-2690. |